A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of ...

Three of the viruses — flu, COVID-19 and RSV — are respiratory viruses and spread from person to person through germ-filled ...

No writing assistance was utilized in the production of this manuscript. Worldwide, respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants.

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Diagnostics Market is witnessing steady growth, with an estimated market valuation of USD 5.93 billion in 2023. The market is expected to expand at a CAGR of 5.81% from 2024 to 2032, driven by rising ...

The shot, also known as the mRESVIA is used for preventing the lower respiratory tract disease in older adults. As per the ...

The recent norovirus outbreak has led scientists to consider the threat of a “quademic” this winter. The Quademic consists of ...

Advancements in prevention strategies against respiratory syncytial virus (RSV) are transforming pediatric care. Experts recommend the use of prophylactic monoclonal antibodies for immunizing infants.

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

As the Texas measles outbreak grows and HHS head RFK Jr. puts vaccines under new scrutiny, two experts answer questions about the public health tool.

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.